A Phase 3, Multicenter, Open-label, Basket, Long-term Extension Study to Evaluate the Safety of Guselkumab in Pediatric Participants with Crohn’s Disease, Ulcerative Colitis, or Juvenile Psoriatic Arthritis

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509560-16-00

Acronym

CNTO1959ISD3001

Enrollment

Registered

2024-07-05

Start date

2024-10-29

Completion date

Unknown

Last updated

2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile psoriatic arthritis (jPsA), Moderately to severely active Crohn's disease (CD), Moderately to severely active ulcerative colitis (UC)

Brief summary

No primary or secondary endpoints will be collected in this study.

Interventions

DRUGGuselkumab

DRUGGuselkumab - solution for injection in pre-filled syringe - 100 mg/mL

Eligibility

Sex/Gender

All

Age

0 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
No primary or secondary endpoints will be collected in this study.	—

Countries

France, Germany, Italy, Norway, Poland, Portugal, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026